Streptococcus agalactiae, also known as Group B Streptococcus (GBS), is a bacterium that can cause infections in humans, particularly in newborns and pregnant women. These infections include neonatal sepsis, pneumonia, meningitis, and urinary tract infections. It is responsible for nearly 100,000 deaths in newborns, at least 46,000 prenatal deaths, and significant long-term disability. Available data estimates that GBS is responsible for around 14,000 cases of neonatal sepsis in Europe each year.
Clindamycin-resistant Streptococcus agalactiae accounts for over 40% of infections, and resistance to a related antibiotic called erythromycin is even more common, exceeding 50%. This severely limits the options for prevention and treatment of GBS infections.
Hifas Biologics’ samples with actitivity against this pathogen